A5025004185- Blood Pressure and Hypertension Studies
- Pulmonary Hypertension Research and Treatments
- Heart Failure Treatment and Management
- Cardiac Imaging and Diagnostics
- Machine Learning in Healthcare
- Hormonal Regulation and Hypertension
- Explainable Artificial Intelligence (XAI)
- Chronic Disease Management Strategies
- Cardiovascular Issues in Pregnancy
- Phosphodiesterase function and regulation
- Forensic Toxicology and Drug Analysis
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cardiovascular Function and Risk Factors
- Cardiac electrophysiology and arrhythmias
- Artificial Intelligence in Healthcare
- Chronic Kidney Disease and Diabetes
- Injury Epidemiology and Prevention
- Autoimmune Bullous Skin Diseases
- Drug-Induced Adverse Reactions
- Environmental and biological studies
- Cardiovascular Effects of Exercise
- Diabetes Treatment and Management
- Atrial Fibrillation Management and Outcomes
- Apelin-related biomedical research
- Biomedical Text Mining and Ontologies
University Medical Center Groningen
2024
Bayer (Germany)
2022-2024
Universidade de São Paulo
2012
Faculdade de Ciências Médicas de Minas Gerais
2005
In chronic kidney disease (CKD) the nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway is impaired. Runcaciguat, an sGC activator, activates heme-free sGC, restoring cGMP production. This phase 2a trial studied efficacy, safety, and tolerability of runcaciguat in CKD patients with or without sodium-glucose co-transporter-2 inhibitor (SGLT2i).
<p class="first" dir="auto" id="d3297097e212"> <b>Background and Aims:</b> Soluble guanylate cyclase (sGC) is a key enzyme in the nitric oxide–cyclic guanosine monophosphate (NO-cGMP) pathway. Oxidative stress impairs NO binding to sGC, preventing formation of cGMP, contributing CKD progression accelerating cardiovascular (CV) disease patients with CKD. Runcaciguat, novel sGC activator, potently selectively activates hem-free form under oxidative stress, independently NO. Activated increases...
Objectives: Cocaine is a commonly used illicit drug that leads to the most emergency department (ED) visits. Chest pain common presentation, reported in 40% of patients. Our aim was evaluate incidence previous myocardial infarction among young cocaine users (18–40 years) with cocaine-associated chest by assessment fibrosis cardiovascular MRI. Second, we also intended coronary tree CT angiography (CTA). Methods: 24 (22 males) who frequently complained about underwent CTA and Mean age patients...
<b>Background:</b> Pulmonary arterial hypertension (PAH) treatment guidelines recommend patients achieve/maintain a low-risk profile. Many treated with PAH-targeted therapy do not meet this goal. <b>Aim:</b> Compare switching to riociguat (RIO) continued phosphodiesterase type 5 inhibitors (PDE5i) in intermediate risk PAH. <b>Methods:</b> REPLACE (NCT02891850) was randomized, open-label, 24-week Phase 4 study. Patients WHO functional class [FC] III, 6-minute walking distance [6MWD] 165–440 m...
Background: Large and deep electronic health record (EHR) datasets have the potential to increase understanding of real-world patient journeys, identify subgroups patients currently grouped with a common disease label but differing in outcomes medical need. However, working EHRs is still relatively new challenging due heterogeneous nature data. Increasing interest machine learning (ML)-based EHR aggregation mostly method-driven, i.e., building on available or newly developed methods. These...
Introduction: Finerenone is a non-steroidal, selective antagonist of the mineralocorticoid receptor (MR), which blocks MR-mediated sodium reabsorption and MR overactivation. In this biomarker substudy to FIDELITY, pooled, pre-specified analysis FIGARO-DKD FIDELIO-DKD, NT-proBNP cardiac troponin T (cTnT) levels were assessed explore effect finerenone on markers. FIDELIO-DKD two phase III trials investigating efficacy safety vs. placebo (PLC) cardiorenal outcomes, in patients with T2D CKD....
Angioedema is a rare reaction to streptokinase, acute and potentially fatal, which should be quickly diagnosed treated guarantee the best prognosis for patient. We describe here case of 65-year-old man, who displayed an anaphylactic after beginning thrombolysis with was treated, remained hospitalized one week in Intensive Care Unit.
The availability of large and deep electronic healthcare records (EHR) datasets has the potential to enable a better understanding real-world patient journeys, identify novel subgroups patients. ML-based aggregation EHR data is mostly tool-driven, i.e., building on available or newly developed methods. However, these methods, their input requirements, and, importantly, resulting output are frequently difficult interpret, especially without in-depth science statistical training. This...